

October 23, 2023

Rachelle Jacques  
Chief Executive Officer  
Akari Therapeutics Plc  
22 Boston Wharf Road FL 7  
Boston, MA 02210

Plc  
Statement on Form F-3  
2023

Re: Akari Therapeutics  
Registration  
Filed October 20,  
File No. 333-275119

Dear Rachelle Jacques:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Drory at 202-551-8342 with any questions.

Please contact Jason

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc:

Win Rutherford